PDUFA VI: Biosimilar Meetings Could Be Model For Earlier User Fee Payments
This article was originally published in The Pink Sheet Daily
Executive Summary
Staggering the payment of fees during product development rather than paying all on application submission could enhance FDA's ability to hold timely meetings with sponsors, Avalere Senior VP Woollett says.